RT Journal Article
SR Electronic
T1 Public Perception of COVID-19 Vaccines through Analysis of Twitter Content and Users
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.19.21255701
DO 10.1101/2021.04.19.21255701
A1 Sameh N. Saleh
A1 Samuel A. McDonald
A1 Mujeeb A. Basit
A1 Sanat Kumar
A1 Reuben J. Arasaratnam
A1 Trish M. Perl
A1 Christoph U. Lehmann
A1 Richard J. Medford
YR 2021
UL http://medrxiv.org/content/early/2021/04/22/2021.04.19.21255701.abstract
AB Twitter is a robust medium to understand wide-scale, organic public perception about the COVID-19 vaccine. In this cross-sectional observational study, we evaluated 2.4 million English tweets from nearly 1 million user accounts matching keywords ((‘covid*’ OR ‘coronavirus’) AND ‘vaccine’) during vaccine development from Feb 1st through Dec 11th, 2020. We applied topic modeling, sentiment and emotion analysis, and demographic inference of users on the COVID-19 vaccine related tweets to provide insight into the evolution of public attitudes. Individuals generated 87.9% (n=834,224) of tweets. Of individuals, men (n=560,824) outnumbered women (n=273,400) by 2:1 and 39.5% (n=329,776) of individuals were ≥ 40 years old. Daily mean sentiment fluctuated congruent with news events, but overall trended positively. Trust, anticipation, and fear were the three most predominant emotions; while fear was the most predominant emotion early in the study period, trust outpaced fear from April 2020 onward. Fear was more prevalent in tweets by individuals (26.3% vs. organizations 19.4%; p<0.001), specifically among women (28.4% vs. males 25.4%; p <0.001). Multiple topics had a monthly trend towards more positive sentiment. Tweets comparing COVID-19 to the influenza vaccine had strongly negative early sentiment but improved over time. Our findings are concerning for COVID-19 vaccine hesitancy, but also identify targets for educational interventions.Competing Interest StatementDr. Lehmann reports stock ownership in Celanese Corporation and Colfax Corporation. There are no other competing interests.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of Texas Southwestern Human Research Protection Program Policies, Procedures, and Guidance did not require institutional review board approval as all data were publicly available.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available upon request. Please request from the corresponding author.